(49 days)
Not Found
No
The device description and performance studies focus on a standard kinetic Jaffe chemical reaction and its measurement using a bichromatic rate technique. There is no mention of AI, ML, or any computational methods beyond standard statistical analysis for performance evaluation.
No
This device is an in vitro diagnostic test for measuring creatinine, which is used for diagnosis and monitoring of renal disease, not for direct treatment of disease.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states, "The CRE2 method is an in vitro diagnostic test for the quantitative measurement of creatinine in human serum, plasma, and urine on the Dimension Vista® System." This directly indicates it is a diagnostic device.
No
The device is a reagent cartridge that uses a chemical reaction (modified kinetic Jaffe technique) to measure creatinine. This involves physical components and chemical processes, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The document explicitly states: "The CRE2 method is an in vitro diagnostic test for the quantitative measurement of creatinine in human serum, plasma, and urine..." This directly identifies the device as an IVD.
- Device Description: The description details a chemical reaction ("modified kinetic Jaffe technique") that occurs in vitro (outside the body) using biological samples (serum, plasma, urine) to measure an analyte (creatinine). This is characteristic of an IVD.
- Purpose: The intended use further clarifies that the measurements are "used in the diagnosis and treatment of certain renal disease, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes." These are all clinical purposes for which an IVD would be used.
N/A
Intended Use / Indications for Use
The CRE2 method is an in vitro diagnostic test for the quantitative measurement of creatinine in human serum, plasma, and urine on the Dimension Vista® System. Creatinine measurements are used in the diagnosis and treatment of certain renal disease, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.
Product codes (comma separated list FDA assigned to the subject device)
CGX
Device Description
The Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge uses a modified kinetic Jaffe technique. In the presence of a strong base such as sodium hydroxide, picrate reacts with creatinine to form a red chromophore. The rate of increasing absorbance at 510 nm due to the formation of this chromophore is directly proportional to the creatinine concentration in the sample and is measured using a bichromatic (510, 577 nm) rate technique.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Method Comparison:
- Predicate device: Dimension Vista® Creatinine (CREA) Flex reagent cartridge (K061238)
- 140 remnant de-identified serum patient samples tested, resulting in a slope of 1.02, intercept of -0.11, and correlation coefficient of 1.000 (range 0.38 – 18.93 mg/dL).
- 112 remnant de-identified urine samples tested, resulting in a slope of 1.05, intercept of -4.29, and correlation coefficient of 0.999 (range 8.39 – 299.60 mg/dL).
- IDMS reference method comparison:
- 48 native remnant de-identified serum patient samples tested, resulting in a slope of 1.06, intercept of -0.03, and correlation coefficient of 0.997 (range 0.18–6.32 mg/dL).
Serum Plasma Equivalency:
- 56 matched serum and lithium heparin plasma samples tested.
- Results: Slope 1.03, Intercept -0.002, Correlation Coefficient (r) 0.998.
- Range: 0.418 - 17.9.
Precision:
- Study performed in accordance with CLSI EP05-A2 over 20 days, two separate runs, with two test samples for each test material.
- Serum Pool 1: Mean 1.30 mg/dL, Repeatability SD 0.03, %CV 2.2; Within-Lab SD 0.04, %CV 2.7.
- Serum Pool 2: Mean 16.8 mg/dL, Repeatability SD 0.09, %CV 0.6; Within-Lab SD 0.11, %CV 0.7.
- BioRad Multiqual Level 1: Mean 0.530 mg/dL, Repeatability SD 0.02, %CV 2.9; Within-Lab SD 0.02, %CV 4.0.
- BioRad Multiqual Level 2: Mean 1.87 mg/dL, Repeatability SD 0.02, %CV 1.1; Within-Lab SD 0.05, %CV 2.5.
- BioRad Multiqual Level 3: Mean 7.23 mg/dL, Repeatability SD 0.05, %CV 0.7; Within-Lab SD 0.08, %CV 1.1.
- Urine Pool 1: Mean 37.2 mg/dL, Repeatability SD 0.91, %CV 2.4; Within-Lab SD 1.33, %CV 3.6.
- Urine Pool 2: Mean 254 mg/dL, Repeatability SD 1.88, %CV 0.7; Within-Lab SD 2.58, %CV 1.0.
- BioRad Liquicheck Level 1: Mean 62.0 mg/dL, Repeatability SD 0.75, %CV 1.2; Within-Lab SD 1.38, %CV 2.2.
- BioRad Liquicheck Level 2: Mean 145 mg/dL, Repeatability SD 1.53, %CV 1.1; Within-Lab SD 2.93, %CV 2.0.
Limit of Blank and Limit of Detection:
- Protocol followed CLSI EP17-A2.
- Serum: LoB 0.030 mg/dL (claim 0.05 mg/dL), LoD 0.056 mg/dL (claim 0.1 mg/dL).
- Urine: LoB 0.438 mg/dL (claim 1.0 mg/dL), LoD 0.828 mg/dL (claim 2.0 mg/dL).
Limit of Quantitation:
- Serum and plasma LoQ: 0.15 mg/dL based on allowable total error of 0.15 mg/dL.
- Urine LoQ: 5.00 mg/dL based on allowable total error of 3.00 mg/dL.
Linearity (Measurement Range):
- Evaluated using 12 equally spaced samples across the assay range.
- Serum (0.00 – 21.9 mg/dL): Slope 0.996, Intercept -0.05, Correlation Coefficient 1.0.
- Urine (1.71 – 338 mg/dL): Slope 0.995, Intercept 0.47, Correlation Coefficient 1.0.
Analytical Specificity (Non-interfering Substances):
- CLSI EP7A2 followed. Substances listed with concentrations showed %Diff usually within +/- 3%, with Some at 6% or 9% and one instance of -9% and 6% difference for protein substances.
Analytical Specificity (Interfering Substances):
- Acetone:
- 150 mg/dL: 18% diff (High CRE2 pool)
- 37.5 mg/dL: 15% diff (Low CRE2 pool)
- Cefoxitin:
- 2.5 mg/dL: 13% diff (Low CRE2 pool)
- Cephalothin:
- 15 mg/dL: 10.1% diff (Low CRE2 pool)
- Glucose:
- 400mg/dL: 12% diff (Low CRE2 pool)
- 300mg/dL: 10% diff (Low CRE2 pool)
- Pyruvate:
- 10.5 mg/dL: 16% diff (High CRE2 pool)
- Triglycerides:
- 3000 mg/dL: 12% diff (High CRE2 pool)
- 2000 mg/dL: 13% diff (Low CRE2 pool)
Hemolysis, Icterus, Lipemia (HIL) Interference:
- Intralipid 20%:
- 2000mg/dL: 15.5% diff (High CRE2 pool)
- 1500mg/dL: 15.1% diff (Low CRE2 pool)
- Bilirubin (unconj) 40mg/dL: -29.6% diff (Low CRE2 pool for 0.98 Mean Test CRE2 Result)
- Bilirubin (conj) 40mg/dL: -16.1% diff (Low CRE2 pool for 1.16 Mean Test CRE2 Result)
Expected Values:
- Serum and Plasma:
- Males: 53 samples, 5 outside range (9.4%).
- Females: 40 samples, 2 outside range (5.0%).
- Urine:
- Males: 22 samples, 2 outside range (9.1%).
- Females: 20 samples, 1 outside range (5.0%). All support published ranges.
Reportable Range Dilution:
- Serum: 1/2 sample volume (6.6 µL) for auto-dilution; extends reportable range to 40.0 mg/dL. % Bias -3.0%.
- Urine: Auto-dilute 3x with water; extends reportable range to 900 mg/dL. % Bias -8.6%.
- Mean percent recovery met 90 - 110% acceptance criteria for extended range protocols.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1225 Creatinine test system.
(a)
Identification. A creatinine test system is a device intended to measure creatinine levels in plasma and urine. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.(b)
Classification. Class II.
0
1. 510(k) Summary
1.1 Description
Dimension Vista® System Creatinine (CRE2) Flex® reagent cartridge
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.
in vitro
diagnostic test for the quantitative
measurement of creatinine in
human serum, plasma, and urine
on the Dimension Vista®
System. Creatinine measurements
are used in the diagnosis and
treatment of certain renal disease,
in monitoring renal dialysis, and as
a calculation basis for measuring
other urine analytes. | The CREA method is an in vitro
diagnostic test for the quantitative
measurement of creatinine in
human serum, plasma and urine
on the Dimension Vista® System. |
| Device
Technology
(detection) | Modified Jaffe Methodology
(creatinine alkaline picrate) with
photometric detection | Same |
| Calibration
Interval | 90 days - same reagent lot | Same |
| Limit of Blank/
Analytical
Sensitivity | Limit of Blank: 0.05 mg/dL | Analytical Sensitivity : 0.1 mg/dL |
| Calibration | Chem 1 Calibrator (K061838)
2 levels (n=5) | Same |
| Traceability &
Standardization | NIST SRM 914a (IDMS assigned
crystalline creatinine standard
prepared by the National Institute of
Standards and Technology) | Same |
| Feature | New Device
Dimension Vista® System
Creatinine (CRE2) Flex® reagent
cartridge | Predicate Device
Dimension Vista® System
Creatinine (CREA) Flex® reagent
cartridge (K061238) |
| Measuring Range
(serum) | 0.15 - 20.0 mg/dL | 0.10 - 20.00 mg/dL |
| Measuring Range
(urine) | 5.00 - 300 mg/dL | 0.10 - 200.00 mg/dL |
| Reportable
Range (serum) | 0.15 - 40.0 mg/dL | 0.10 - 40.00 mg/dL |
| Reportable
Range (urine) | 5.00 - 900 mg/dL | 0.10 - 200.00 mg/dL (no specific
dilution factor recommended) |
| Sample Volume | 13.2 µL | 8 µL |
| Reagents | Reagent 2 = Lithium Picrate
(125 mM)
Reagent 1 = Sodium Hydroxide
(1000 mM) | Reagent 1 = Lithium Picrate
(125 mM)
Reagent 2 = Sodium Hydroxide
(2000 mM) and potassium
ferricyanide |
| Reagent Volumes | Volume of Reagent 1 used = 30.6 µL
Volume of Reagent 2 used = 16.5 µL | Volume of Reagent 1 used = 29.6 µL
Volume of Reagent 2 used = 7.2 µL |
| Detection
Conditions | Wavelength = 510 and 577 nm
Type of Measurement =
Bichromatic rate | Wavelength = 510 and 600 nm
Type of Measurement =
Bichromatic rate |
| Expected Values | Serum and Plasma
Males: 0.700 - 1.30 mg/dL
Females: 0.550 - 1.02 mg/dL
Urine
Males: 0.95 - 2.49 g/24 hr | Serum and Plasma
0.6-1.3 mg/dL
Urine
0.6-2.5 g/24hr |
| | Females: 0.60 - 1.80 g/24 hr | |
| | No significant interference at a
Creatinine.concentration of 1.5
mg/dL in serum from:
Hemoglobin at 1000 mg/dL
Bilirubin (conjugated) at 20 mg/dL,
Lipemia (Intralipid) at 1000 mg/dL | No significant interference at a
Creatinine concentration of 1.3
mg/dL in serum from:
Hemoglobin at 500 mg/dL,
Bilirubin (conjugated) at 20 mg/dL,
Lipemia (Intralipid) at 3000 mg/dL |
| Interferences | | |
| | Bilirubin (unconjugated) at 20
mg/dL | No significant interference at a
Creatinine concentration of 1.1
mg/dL from:
Bilirubin (unconjugated) at 10
mg/dL |
Page 3 of 17
3
Differences for the Dimension Vista Creatinine (CRE2) Flex® reagent cartridge:
Page 4 of 17
4
1.12 Standard/Guidance Document Reference
- Stability Testing of In Vitro Diagnostic Reagents (CEN 13640) t
- Interference Testing in Clinical Chemistry; Approved Guideline (EP07-A2) .
- Method Comparison and Bias Estimation Using Patient Samples; Approved . Guideline (EP09-A2-IR).
- Evaluation of Precision Performance of Quantitative Measurement Methods: . Approved Guideline (EP05-A2)
- Evaluation of the Linearity of Quantitative Measurement (EP-06-A) .
- Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; . Approved Guideline (EP17-A2)
- Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; . Approved Guideline- Third Edition (C28-A3c)
- In Vitro Diagnostic Creatinine Test System Guidance for Industry July 2, 1998 .
- In Vitro Diagnostic Devices: Guidance for the Preparation of 510(k) Submissions -. Jan. 1997
- Format for Traditional and Abbreviated 510(k)'s Guidance for Industry and Staff -. Nov. 17, 2005
- Guidance for Industry and FDA Staff: Administrative Procedures for CLIA . Categorization - May 7, 2008
- eCopy Program for Medical Device Submissions Guidance for Industry and Food . and Drug Administration Staff - October 10, 2013
- Refuse to Accept Policy for 510(k)s Guidance for Industry and Food and Drug . Administration Staff - December 31, 2012
Page 5 of 17
5
1.13 Performance Characteristics
The following data represent typical method performance. These data were collected on the Dimension Vista® 500 System.
1.13.1 Method Comparison
The predicate device selected for the method comparison was the Dimension Vista® Creatinine (CREA) Flex reagent cartridge cleared under K061238. Remnant de-identified serum samples were tested. No patient history information was obtained on these samples. Inclusion/exclusion data criteria are not applicable. The study included both native and spiked samples. ·
These studies were conducted internally by Siemens Healthcare Diagnostic Inc. R&D organization personnel. The personnel conducting the study were laboratory technicians with training similar to personnel who would conduct the tests in a hospital laboratory setting. They were trained on the operation of both the device and the predicate device. A split sample method comparison, following EP09-A2, demonstrated good agreement between the Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge and the predicate Dimension Vista® Creatinine (CREA) Flex® reagent cartridge with serum patient samples.
One hundred forty serum patient samples across the assay range were tested on the Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge and the Dimension Vista® Creatinine (CREA) Flex® reagent cartridge. In a second study, 112 urine samples were tested on the Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge and the Dimension Vista Creatinine (CREA) Flex® reagent cartridge. The results across the full assay range were analyzed by linear regression. Although the samples were tested in duplicate, only the first result was used for the analysis.
| Comparative
Method | Range
(mg/dL) | Slope | Intercept
(mg/dL) | Correlation
Coefficient | n | Sample
type |
|-----------------------|------------------|-------|----------------------|----------------------------|-----|----------------|
| Vista CREA
Assay | 0.38 – 18.93 | 1.02 | -0.11 | 1.000 | 140 | serum |
| Vista CREA
Assay | 8.39 – 299.60 | 1.05 | -4.29 | 0.999 | 112 | urine |
The model equation for the regression statistics is: [results for Dimension Vista® Creatinine (CRE2)] = slope x [comparative method results] + intercept.
An additional study was completed comparing the Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge with the IDMS reference method. Remnant de-identified serum samples were tested. No patient history information was obtained on these samples. Inclusion/exclusion data criteria are not applicable. All of the samples were native.
Forty eight patient samples were tested on the Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge and the IDMS reference method. The results were analyzed by linear
Page 6 of 17
6
regression. Although the samples were tested in duplicate, only the first result was used for the analysis.
| Comparative
Method | Range
(mg/dL) | Slope | Intercept
(mg/dL) | Correlation
Coefficient | n | Sample
type |
|-----------------------------|------------------|-------|----------------------|----------------------------|----|----------------|
| IDMS
Reference
Method | 0.18–6.32 | 1.06 | -0.03 | 0.997 | 48 | serum |
The model equation for the regression statistics is: [results for Dimension Vista® Creatinine (CRE2)] = slope x [comparative method results] + intercept.
1.13.2 Serum Plasma Equivalency
Serum and lithium heparin plasma equivalency was demonstrated for the Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge. Fifty six matched serum and lithium heparin plasma samples were tested using the Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge. The table below summarizes the linear regression statistics.
| Serum vs. | Slope | Intercept | Correlation
Coefficient (r) | Range | n |
|---------------------------|-------|-----------|--------------------------------|--------------|----|
| Lithium Heparin
Plasma | 1.03 | -0.002 | 0.998 | 0.418 - 17.9 | 56 |
One replicate of each sample was processed. All samples in the study were fresh and never frozen. The eight spiked sample sets were prepared by spiking equal amounts of purified creatinine into the matched serum and lithium heparin plasma samples.
1.13.3 Precision
Precision testing was performed in accordance with CLSI EP05-A2 Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline - Second Edition. Samples consisted of two (2) serum pools, three (3) levels of BioRad Multiqual material, two (levels) of BioRad Liquicheck material and two (2) urine pools. Testing was performed over twenty (20) days, two (2) separate runs with two test samples for each test material. Analysis of variance (ANOVA) was used to evaluate the data consistent with the recommendations of EP05-A2. The data are summarized in the following table:
Page 7 of 17
7
| Repeatability | Within-Lab | |||||
|---|---|---|---|---|---|---|
| Sample | Mean | |||||
| (mg/dL) | SD | %CV | SD | %CV | ||
| Serum Pool 1 | 1.30 | 0.03 | 2.2 | 0.04 | 2.7 | |
| erun | Serum Pool 2 | 16.8 | 0.09 | 0.6 | 0.11 | 0.7 |
| BioRad Multiqual | ||||||
| Level 1 | 0.530 | 0.02 | 2.9 | 0.02 | 4.0 | |
| BioRad Multiqual | ||||||
| Level 2 | 1.87 | 0.02 | 1.1 | 0.05 | 2.5 | |
| BioRad Multiqual | ||||||
| Level 3 | 7.23 | 0.05 | 0.7 | 0.08 | 1.1 | |
| Jrine | Urine Pool 1 | 37.2 | 0.91 | 2.4 | 1.33 | 3.6 |
| Urine Pool 2 | 254 | 1.88 | 0.7 | 2.58 | 1.0 | |
| BioRad Liquicheck | ||||||
| Level 1 | 62.0 | 0.75 | 1.2 | 1.38 | 2.2 | |
| BioRad Liquicheck | ||||||
| Level 2 | 145 | 1.53 | 1.1 | 2.93 | 2.0 |
BioRad® is a registered trademark of Bio-Rad Laboratories, Irvine, CA 92618, USA. Multiqual® is a registered trademark of Bio-Rad Laboratories, Irvine, CA 92618, USA. Liquichek™ is a trademark of Bio-Rad Laboratories, Irvine, CA 92618, USA.
.
8
1.13.4 Limit of Blank and Limit of Detection
The Limit of Blank (LoB) and Limit of Detection (LoD) were evaluated in accordance with CLSI EP17-A2 Protocols for Determination of Limits of Detection and Limits of Quantitation: Approved Guideline.
| Dimension Vista® CRE2 Limit of Detection Results with Serum | ||
|---|---|---|
| Limit | Protocol | Value |
| LoB | 4 samples with no analyte | |
| were tested (N=5) for 3 | ||
| days, one run per day, 2 | ||
| reagent lots, | 0.030 mg/dL | |
| LoD | 4 low patient serum | |
| samples were tested | ||
| (N=5) for 3 days, one run | ||
| per day, 2 reagent lots | 0.056 mg/dL |
| Dimension Vista® CRE2 Limit of Detection Results with Urine | ||
|---|---|---|
| Limit | Protocol | Value |
| LoB | 4 samples with no analyte | |
| were tested (N=5) for 3 | ||
| days, one run per day, 2 | ||
| reagent lots, | 0.438 mg/dL | |
| LoD | 4 low patient urine | |
| samples were tested | ||
| (N=5) for 3 days, one run | ||
| per day, 2 reagent lots | 0.828 mg/dL |
The nonparametric approach described in EP-17A2 was followed to determine the Limit of Detection.
LoB = Mean of Blank Measurement + 1.645 x Standard Deviation of Blank Measurements LoD = Limit of Blank + CpSDs
• Co is a correction factor for the 95% Cl normal variate to account for bias in the SDs estimate.
· SDs is an estimate of method imprecision pooled from replicates of the low analyte samples
9
The LoB was determined to be 0.030 mg/dL with serum samples and is consistent with the claim of 0.05 mg/dL. With urine samples, the LoB was determined to be 0.438 mg/dL and is consistent with the claim of 1.0 mg/dL.
The LoD was determined to be 0.056 mg/dL with serum samples and is consistent with the claim of 0.1 mg/dL. With urine samples, the LoD was determined to be 0.828 mg/dL and is consistent with the claim of 2.0 mg/dL.
1.13.5 Limit of Quantitation
The Limit of Quantitation (LoQ) for CRE2 for serum and plasma is 0.15 mg/dL and based on allowable total error of 0.15 mg/dL, determined consistent with CLSI Guideline EP17-A2. Total Error is calculated using: TE = bias + 2 * SD. The reference values are traceable to Isotope Dilution Mass Spectrometry (IDMS). The established allowable total error for creatinine published by CLIA¹, CAP2, AAB3, NYS4 and WLSH is +/- 0.3 mg/dL or +/- 15% (greater). The LoQ of 0.15 mg/dL based on allowable total error of 0.15 ma/dL meets these recommendations.
CLIA' - CLIA '88 Proficiency Testing Limits, U.S. Federal Register.
CAP2 - College of American Pathologists Participant Summary, April 2004.
- AAB American Association of Bioanalysts Table of Grading Limits (undated, approx Oct 2005). For details, visit www.aab.org/pts/grdlim.htm
- NYS® Wadsworth Center Clinical Laboratory Evaluation Program, Guide to Program Requirements and Services. New York State Department of Health (undated, approx June, 2004). For details, visit www.wadsworth.org/labcert.
- WLSH WSLH Proficiency Testing is a national, full-service PT program located at the Wisconsin State Laboratory of Hygiene on the campus of the University of Wisconsin - Madison. (undated, approx June, 2004). For more information, visit www.sh.wisc.edu/pt.
The Limit of Quantitation (LoQ) for CRE2 for urine is 5.00 mg/dL and based on allowable total error of 3.00 mg/dL, determined consistent with CLSI Guideline EP17-A2. Total Error is calculated using: TE = bias + 2 * SD. The reference values are traceable to Isotope Dilution Mass Spectrometry (IDMS). There is no recognized allowable total error limit for urine creatinine measurements.
Page 10 of 17
10
1.13.6 Linearity (Measurement Range)
Linearity was evaluated for serum and urine samples by using 12 equally spaced samples which spanned the assay range. Each was prepared by mixing high and low creatinine concentration samples across the measurement range as described in CLSI Evaluation of the Linearity of Quantitative Measurement Procedure (EP06-A). The low sample represents an artificial sample matrix prepared with bovine serum albumin.
Regression Statistics
| Range of samples | Slope | Intercept | Correlation
Coefficient | N |
|----------------------------|-------|-----------|----------------------------|----|
| serum
0.00 – 21.9 mg/dL | 0.996 | -0.05 | 1.0 | 12 |
| urine
1.71 – 338 mg/dL | 0.995 | 0.47 | 1.0 | 12 |
1.14 Analytical Specificity
12.5.1 Non-interfering Substances
CLSI EP7A2 was followed for the interference testing. The interference study was conducted using a "paired difference worst case scenario" approach where these compounds were spiked into fresh sample pools containing either low or high levels of creatinine analyte in both serum pools and urine pools.
11
| DV CRE2 Serum/Plasma Substance | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| DV CRE2 | |||||||||
| Substance | Concentration of | ||||||||
| Substance (mg/dL) | LOW pool (~1.5mg/dL) | HIGH pool (~5.0 mg/dL) | |||||||
| Mean | Control | % Diff | mean | control | % Diff | ||||
| Acetaminophen | 20 | 1.41 | 1.40 | 1% | 5.03 | 5.00 | 1% | ||
| Acetoacetate | 20 | 1.35 | 1.38 | -3% | 4.87 | 4.87 | 0% | ||
| Amikacin | 8 | 1.40 | 1.40 | 0% | 5.05 | 5.00 | 1% | ||
| Ampicillin | 5.3 | 1.43 | 1.40 | 2% | 5.06 | 5.00 | 1% | ||
| Ascorbic Acid | 6 | 1.41 | 1.40 | 0% | 4.99 | 5.00 | 0% | ||
| Caffeine | 6 | 1.40 | 1.42 | -2% | 4.97 | 4.96 | 0% | ||
| Carbamazepine | 3 | 1.43 | 1.42 | 1% | 5.01 | 5.06 | -1% | ||
| Cephalexin | 25 | 1.35 | 1.38 | -3% | 4.86 | 4.87 | 0% | ||
| Cephapirin | 25 | 1.43 | 1.39 | 3% | 4.99 | 4.97 | 0% | ||
| Cephradine | 25 | 1.44 | 1.39 | 3% | 5.00 | 4.97 | 1% | ||
| Chloramphenicol | 5 | 1.43 | 1.41 | 1% | 5.01 | 5.03 | 0% | ||
| Chlordiazepoxide | 1 | 1.40 | 1.43 | -2% | 5.01 | 5.02 | 0% | ||
| Chlorpromazine | 0.2 | 1.40 | 1.40 | 0% | 5.00 | 4.99 | 0% | ||
| Cholesterol Supertrate | 503 | 1.34 | 1.30 | 3% | 4.58 | 4.57 | 0% | ||
| Cimetidine | 2 | 1.40 | 1.42 | -1% | 4.97 | 4.96 | 0% | ||
| Dextran 40 | 6000 | 1.56 | 1.51 | 3% | 5.13 | 5.23 | -2% | ||
| Diazepam | 0.51 | 1.44 | 1.43 | 1% | 5.04 | 5.02 | 0% | ||
| Digoxin | 6.1 ng/mL | 1.41 | 1.42 | 0% | 4.95 | 4.93 | 0% | ||
| EDTA | 200 | 1.37 | 1.39 | -2% | 4.93 | 4.91 | 0% | ||
| Erythromycin | 6 | 1.44 | 1.41 | 2% | 5.00 | 5.03 | -1% | ||
| Ethanol | 400 | 1.41 | 1.40 | 0% | 4.98 | 5.00 | 0% | ||
| Ethosuximide | 25 | 1.40 | 1.42 | -1% | 4.97 | 4.96 | 0% | ||
| Furosemide | 6 | 1.43 | 1.41 | 1% | 5.03 | 5.03 | 0% | ||
| Gentamicin | 1 | 1.42 | 1.40 | 1% | 5.00 | 5.00 | 0% | ||
| Heparin (196 Units/mg) | 3 U/mL | 1.40 | 1.42 | -1% | 4.94 | 4.99 | -1% | ||
| Ibuprofen | 50 | 1.43 | 1.42 | 1% | 5.01 | 5.06 | -1% | ||
| Immunoglobulin G (IgG) | 5000 | 1.56 | 1.51 | 3% | 5.14 | 5.23 | -2% | ||
| Isopropanol | 1.0 g/dL | 1.40 | 1.39 | 0% | 4.91 | 4.91 | 0% | ||
| Lidocaine | 1.2 | 1.43 | 1.41 | 1% | 5.08 | 5.03 | 1% | ||
| Lithium | 2.2 | 1.40 | 1.40 | 0% | 5.00 | 4.99 | 0% | ||
| Nicotine | 0.1 | 1.44 | 1.42 | 1% | 5.05 | 5.06 | 0% | ||
| Nortriptyline | 1000 ng/mL | 1.39 | 1.39 | -1% | 4.96 | 4.91 | 1% | ||
| Penicillin G (1654 | |||||||||
| Units/mg) | 25 U/mL | 1.41 | 1.40 | 1% | 4.98 | 4.99 | 0% | ||
| Pentobarbital | 8 | 1.43 | 1.42 | 0% | 4.99 | 4.98 | 0% | ||
| Phenobarbital | 10 | 1.44 | 1.42 | 1% | 5.00 | 4.98 | 0% | ||
| Phenytoin | 5 | 1.42 | 1.43 | -1% | 5.02 | 5.02 | 0% | ||
| Potassium oxalate | 500 mg/dL | 1.40 | 1.38 | 1% | 4.86 | 4.87 | 0% | ||
| Primidone | 4 | 1.42 | 1.42 | 0% | 5.04 | 5.06 | 0% | ||
| Propoxyphene | 0.16 | 1.42 | 1.43 | 0% | 5.02 | 5.02 | 0% | ||
| Protein, Albumin | 6000 | 1.56 | 1.51 | 3% | 4.88 | 5.345 | -9% | ||
| Protein, Total | 12g/dL | 1.57 | 1.48 | 6% | 5.13 | 5.22 | -2% | ||
| Salicylic acid | 60 | 1.42 | 1.41 | 1% | 5.03 | 5.03 | 0% | ||
| Sodium fluoride | 400 | 1.30 | 1.30 | 0% | 4.62 | 4.67 | -1% | ||
| Theophylline | 4 | 1.39 | 1.42 | -2% | 5.00 | 4.96 | 1% | ||
| Urea | 500 | 1.43 | 1.40 | 2% | 5.04 | 4.99 | 1% | ||
| Uric acid | 20 | 1.43 | 1.41 | 1% | 4.97 | 4.99 | 0% | ||
| Valproic acid | 50 | 1.41 | 1.42 | -1% | 4.97 | 4.96 | 0% | ||
| DV CRE2 Urine Method Specific | |||||||||
| DV CRE2 | |||||||||
| Substance | Concentration of | ||||||||
| Substance | LOW pool (~40 mg/dL) | HIGH pool ( ~ 175 mg/dL) | |||||||
| Mean | Control | %Diff | mean | control | %Diff | ||||
| 50% Acetic Acid | 25mL/24 hr collection | 40.75 | 40.25 | 1% | 180.0 | 178.8 | 1% | ||
| 6N Hydrochloric Acid | 0.60% | 41.30 | 41.35 | 0% | 178.8 | 182.5 | -2% | ||
| 6N Nitric Acid | 0.60% | 41.18 | 41.35 | 0% | 181.3 | 182.5 | -1% | ||
| Acetone | 100 mg/dl. | 42.93 | 41.98 | 2% | 184.5 | 186.8 | -1% | ||
| Albumin | 0.5 g/dL | 42.08 | 42.98 | -2% | 183 | 185.8 | -1% | ||
| Ascorbic Acid | 1.5 g/dl | 38.65 | 40.48 | -5% | 173.5 | 176.0 | -1% | ||
| Bilirubin (conjugated) | 2 mg/dL | 42.08 | 41.75 | 1% | 182.0 | 179.8 | 1% | ||
| Boric Acid | 1% w/v | 41.83 | 41.75 | 0% | 185.8 | 184.0 | 1% | ||
| Ethanol | 1 g/dL | 41.98 | 41.65 | 1% | 183.8 | 179.8 | 2% | ||
| Gamma Globulin | 0.5 g/dL | 42.75 | 41.88 | 2% | 184.3 | 185.5 | -1% | ||
| Glucose | 2 g/dL | 42.65 | 41.88 | 2% | 184.8 | 185.5 | 0% | ||
| Hemoglobin | 115 mg/dL | 41.78 | 41.58 | 0% | 183.8 | 183.8 | 0% | ||
| Oxalic Acid | 0.1 g/dL | 40.28 | 40.48 | 0% | 178.3 | 176.0 | 1% | ||
| Sodium Carbonate | 5g/24 hr collection | 41.08 | 40.65 | 1% | 182.0 | 183.0 | -1% | ||
| Sodium Fluoride | 1% w/v | 41.05 | 41.75 | -2% | 187.3 | 184.0 | 2% |
Page 12 of 17
.
. "
12
12.5.2 Interfering Substances
The Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge was evaluated for interference according to CLSI EP7-A2. Bias is the difference in the results between the control sample (without the interferent) and the test sample (contains the interferent) expressed in percent. Bias exceeding 10% is considered interference. Dilution studies were conducted to determine the level at which the spiked substance no.longer displayed significant interference. These studies were conducted at two creatinine analyte concentrations, if both sample pools show significant interference. This study was conducted as needed for both serum pools and urine pools.
13
| Substance | Concentration of
Substance (mg/dL) | Mean Test
CRE2 | Mean
Control | % Diff |
|---------------|---------------------------------------|-------------------|-----------------|--------|
| Acetone | 150 | 5.77 | 4.87 | 18% |
| Acetone | 75 | 5.32 | 4.87 | 9% |
| Acetone | 37.5 | 5.15 | 4.87 | 6% |
| Acetone | 37.5 | 1.59 | 1.39 | 15% |
| Acetone | 18.75 | 1.50 | 1.39 | 8% |
| Cefoxitin | 5 | 5.29 | 4.97 | 6% |
| Cefoxitin | 2.5 | 1.58 | 1.40 | 13% |
| Cefoxitin | 1.25 | 1.49 | 1.40 | 6% |
| Cephalothin | 15 | 1.53 | 1.39 | 10.1% |
| Cephalothin | 15 | 5.09 | 4.97 | 2% |
| Cephalothin | 13.75 | 1.49 | 1.40 | 6% |
| Glucose | 400mg/dL | 1.54 | 1.37 | 12% |
| Glucose | 300mg/dL | 1.51 | 1.37 | 10% |
| Glucose | 200mg/dL | 1.45 | 1.37 | 6% |
| Glucose | 600mg/dL | 5.15 | 4.91 | 5% |
| Pyruvate | 10.5 mg/dL | 5.67 | 4.87 | 16% |
| Pyruvate | 5.26 mg/dL | 5.31 | 4.92 | 8% |
| Pyruvate | 1.32 mg/dL | 1.49 | 1.38 | 8% |
| Triglycerides | 3000 | 4.93 | 4.39 | 12% |
| Triglycerides | 2500 | 4.97 | 4.57 | 9% |
| Triglycerides | 2000 | 5.01 | 4.65 | 8% |
| Triglycerides | 2000 | 1.49 | 1.32 | 13% |
| Triglycerides | 1500 | 1.48 | 1.35 | 10% |
| Triglycerides | 1000 | 1.50 | 1.39 | 8% |
12.5.3 Hemolysis, Icterus, Lipemia (HIL) Interference
The Dimension Vista® Creatinine (CRE2) Flex reagent cartridge was evaluated for interference according to CLSI EP7-A2. Bias is the difference in the results between the control sample (without the interferent) and the test sample (contains the interferent) expressed in percent. Bias exceeding 10% is considered interference.
Page 14 of 17
14
| DV CRE2 HIL Interference | ||||
|---|---|---|---|---|
| Substance | Concentration of | |||
| Substance (mg/dL) | Mean Test CRE2 | |||
| Result (mg/dL) | Mean Control CRE2 | |||
| Result (mg/dL) | % Diff | |||
| Intralipid 20% | 2000mg/dL | 5.27 | 4.56 | 15.5% |
| Intralipid 20% | 1500mg/dL | 5.15 | 4.71 | 9.5% |
| Intralipid 20% | 1500mg/dL | 1.51 | 1.31 | 15.1% |
| Intralipid 20% | 1000mg/dL | 1.45 | 1.36 | 7.0% |
| Hemoglobin | 1000mg/dL | 1.45 | 1.35 | 7.0% |
| Hemoglobin | 1000mg/dL | 4.87 | 4.72 | 3.2% |
| Bilirubin (unconj) | 40mg/dL | 0.98 | 1.40 | -29.6% |
| Bilirubin (unconj) | 20mg/dL | 1.44 | 1.45 | -0.2% |
| Bilirubin (unconj) | 40mg/dL | 4.61 | 4.93 | -6.6% |
| Bilirubin (conj) | 40mg/dL | 1.16 | 1.38 | -16.1% |
| Bilirubin (conj) | 20mg/dL | 1.38 | 1.44 | -4.5% |
| Bilirubin (conj) | 40mg/dL | 4.72 | 4.94 | -4.5% |
| Bilirubin (conj) | 20mg/dL | 4.96 | 5.04 | -1.5% |
1.15 Expected Values
Serum and Plasma
Transference was used to validate established reference ranges for serum and plasma creatinine following CLSI C28-A3c.
Serum samples from forty normal healthy adult female donors and forty-three normal healthy adult male donors were tested N=1 using the Dimension Vista Creatinine (CRE2) Flex® reagent cartridge. The range was considered validated if ≤10% of the samples fell outside of established range.
| Gender | Males | Females |
|---|---|---|
| Range | 0.700 -1.30 mg/dL | 0.550 -1.02 mg/dL |
| # Samples | 53 | 40 |
| # Sample outside | ||
| Range | 5 | 2 |
| % Samples outside | ||
| range | 9.4% | 5.0% |
ﻟﺴﺴﺴﺴ
These data support the published ranges for Males (0.7 to 1.3 mg/dL (Tietz 1999) and Females (0.55 to 1.02 mg/dL (Clin Chem 54:3 (2008)).
Page 15 of 17
15
Urine
These data support the published ranges for Males (0.7 to 1.3 mg/dL (Tietz 1999) and Females (0.55 to 1.02 mg/dL (Clin Chem 54:3 (2008)).
Similarly published reference ranges were validated for urine specimens using samples from twenty normal healthy adult female donors and twenty-two normal healthy adult male donors following CLSI C28-A3c. Samples were processed N=1 using the Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge. The range was considered validated if ≤10% of the samples fell outside of established range.
| Gender | Males | Females |
|---|---|---|
| Reference Range | 0.95-2.49 g/day | 0.60-1.80 g/day |
| # Samples | 22 | 20 |
| # Sample outside | ||
| Range | 2 | 1 |
| % Samples outside | ||
| range | 9.1% | 5.0% |
These data support the published ranges for Males (0.95 to 2.49 g/day (Clin Chem Acta 344 (2004) 137-148) and Females (0.6 to 1.8 g/day (Tietz 1999).
1.16 Results Outside of the Measuring (Reportable) Range
The instrument generates a flag which states "Above Assay Range" or "Below Assay Range" when it obtains a result outside of the measuring range. Serum and plasma samples with results in excess of 20 mg/dL and urine samples above 300 mg/dL are reported as "above Assay Range" and should be repeated on dilution.
Autodilution for Serum and Plasma Samples: The autodilute sample volume is 6.6 uL and recommended dilution factor 1:2 for serum and plasma. This extends the serum and plasma reportable range to 40 mg/dL.
Autodilution (AD) for Urine Samples: Autodilutions for urines are a two-step process. Urine samples automatically get a 1:15 AUD in the aliquot tray followed by a second 1:3 dilution in the aliquot tray making a final 1:45 dilution. This extends the urine reportable range to 900 mg/dL [79560 umol/L]. Refer to your Dimension Vista® Operator's Guide.
These protocols were tested with samples at the upper end of the undiluted range. The mean percent recovery was calculated and met the acceptance criteria of 90 - 110% recovery.
16
DV CRE2 Reportable Range Dilution of above assay range results
Serum
Serum results > 20 mg/dL can be automatically re-run using 1/2 sample (6.6 µL vs 13.2 µL). This extends the serum reportable range to 40.0 mg/dL.
| Samle Volume (µL) | Mean of N=5 reps |
|---|---|
| 13.2 µL(normal volume) | 16.5 |
| 6.6 µL (auto-dilute volume) | 16.0 |
| % Bias | -3.0% |
Urine
Urine results > 300 mg/dL can be automatically diluted 3x with water and re-run. This extends the urine reportable range to 900 mg/dL.
| Mean of N=5 reps | |
|---|---|
| undiluted (normal) | 268 |
| auto-dilute 3x with water | 245 |
| % Bias | -8.6% |
Conclusion
Results support serum extended range up to 40.0 mg/dL, and urine extended range up to 900 mg/dL.
1.17 Conclusion
The Dimension Vista® Creatinine (CRE2) Flex® reagent cartridge (K1033A) is substantially equivalent in principle and performance to the Dimension Vista® Creatinine (CREA) Flex® reagent cartridge cleared under K061238. Comparative testing described in the submission demonstrates substantially equivalent performance.
Page 17 of 17
17
Image /page/17/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three curved shapes that resemble waves or abstract human figures. The logo is printed in black and white.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 24, 2014
SIEMENS HEALTHCARE DIAGNOSTICS INC. LAURA DUGGAN, PH.D. REGULATORY TECHNICAL SPECIALIST P.O. BOX 6101 NEWARK DE 19714-6101
Re: K133728
Trade/Device Name: Dimension Vista® Creatinine (CRE2) Flex® Reagent Cartridge Regulation Number: 21 CFR 862.1225 Regulation Name: Creatinine test system Regulatory Class: II Product Code: CGX Dated: December 05, 2013 Received: December 6, 2013
Dear Dr. Duggan:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
18
Page 2-Dr. Duggan
If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/McdicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance .
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
CourtneyH.Lias -S
Courtney H. Lias. Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
19
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: December 31, 2013 See PRA Statement on last page.
510(k) Number (if known) K133728
Device Name
Dimension Vista Creatinine (CRE2) Flex Reagent Cartridge
Indications for Use (Describe)
The CRE2 method is an in vitro diagnostic test for the quantitative measurement of creatinine in human serum, plasma, and urine on the Dimension Vista® System. Creatinine measurements are used in the diagnosis and treatment of certain renal discase, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
FORM FDA 3881 (9/13)